DRTS Alpha Tau Medical Ltd Gross Return on Sales

DRTS (Alpha Tau) - company brandmark

Alpha Tau Medical Ltd. (DRTS) is developing the innovative Alpha DaRT method to combat solid tumors, leveraging clinical successes in the US. The technology is being integrated into surgical protocols, creating a unique ecosystem for the targeted destruction of cancer cells. High demand for radiotherapy for advanced forms of cancer is driving the international expansion of its base. The current level of the indicator is 0.00, which clearly demonstrates the gross marginal profit.

Alpha Tau (DRTS): Gross Profitability from 04/28/2023 to 11/20/2026

Analytical breakdowns and data insights for company Alpha Tau Medical Ltd (DRTS)

- stock value and consensus price forecast:
Fundamental valuation:DRTS (Alpha Tau)
Finished products of Alpha Tau Medical

The complexity of radioisotope disposal and strict adherence to nuclear regulations directly impact the production cost structure of Alpha Tau Medical Ltd. (DRTS). The current value of 0.00 reflects the profit margin after deducting direct costs, allowing investors to assess resource management efficiency and pricing strategy through the lens of gross margin.